

# Peripheral T-cell Lymphoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/P5489E88FBEBEN.html>

Date: May 2024

Pages: 128

Price: US\$ 6,499.00 (Single User License)

ID: P5489E88FBEBEN

## Abstracts

The 7 major peripheral T-cell lymphoma markets reached a value of US\$ 608.8 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US\$ 1,003.2 Million by 2034, exhibiting a growth rate (CAGR) of 4.65% during 2024-2034.

The peripheral T-cell lymphoma market has been comprehensively analyzed in IMARC's new report titled "Peripheral T-cell Lymphoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Peripheral T-cell lymphoma is a type of non-Hodgkin lymphoma that originates from mature T-cells or natural killer cells. The common symptoms associated with the ailment include enlarged lymph nodes, fever, night sweats, unexplained weight loss, fatigue, skin rashes or lesions, etc. Some patients may experience various systemic indications, such as generalized itching, bone pain, abdominal discomfort, etc. As the condition can affect multiple organs and systems, they may also develop symptoms related to organ involvement, including respiratory difficulties, gastrointestinal disturbances, neurological manifestations, etc. The diagnosis of peripheral T-cell lymphoma involves a comprehensive evaluation that consists of a clinical examination, imaging studies, and pathological analysis. It typically begins with a physical exam to assess lymph nodes, followed by imaging techniques, such as computed tomography (CT) scans and positron emission tomography (PET) scans, to evaluate the extent of the disease. A biopsy of an affected lymph node or other involved tissues is essential to confirm the diagnosis and determine the specific subtype through histopathological analysis and immunophenotyping. Various additional tests, including molecular or genetic studies, are also conducted to identify genetic abnormalities or viral infections associated with the disease.

The escalating cases of certain genetic mutations and chromosomal abnormalities that disrupt normal cellular processes and lead to the uncontrolled growth of lymphocytes are primarily driving the peripheral T-cell lymphoma market. Furthermore, the inflating adoption of histone deacetylase (HDAC) inhibitors, such as romidepsin or belinostat, since they modulate gene expression and destroy cancerous cells, is acting as another significant growth-inducing factor. Apart from this, the emerging popularity of reduced-intensity conditioning (RIC) regimen, which involves using lower doses of chemotherapy or radiation to prepare the patient for transplantation, thereby decreasing treatment-related toxicity while still achieving immune system reset, is also creating a positive outlook for the market. Additionally, several key players are making extensive investments in R&D activities to introduce dual-targeting therapies that aim to simultaneously inhibit multiple signaling pathways and molecular targets associated with the ailment. This, in turn, is further bolstering the market growth. Moreover, the ongoing advancements in diagnostic procedures, including the launch of genomic profiling and molecular testing techniques, that aid in identifying genetic alterations and molecular subtypes, thereby allowing more personalized and targeted treatment strategies, are expected to drive the peripheral T-cell lymphoma market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the peripheral T-cell lymphoma market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for peripheral T-cell lymphoma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the peripheral T-cell lymphoma market in any manner.

#### Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

## Countries Covered

United States  
Germany  
France  
United Kingdom  
Italy  
Spain  
Japan

## Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario  
Historical, current, and future performance of the peripheral T-cell lymphoma market  
Historical, current, and future performance of various therapeutic categories in the market  
Sales of various drugs across the peripheral T-cell lymphoma market  
Reimbursement scenario in the market  
In-market and pipeline drugs  
Competitive Landscape:  
This report also provides a detailed analysis of the current peripheral T-cell lymphoma marketed drugs and late-stage pipeline drugs.

## In-Market Drugs

Drug Overview  
Mechanism of Action  
Regulatory Status  
Clinical Trial Results  
Drug Uptake and Market Performance

## Late-Stage Pipeline Drugs

Drug Overview  
Mechanism of Action  
Regulatory Status  
Clinical Trial Results  
Drug Uptake and Market Performance

\*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

## Key Questions Answered in this Report:

### Market Insights

How has the peripheral T-cell lymphoma market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the peripheral T-cell lymphoma market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the peripheral T-cell lymphoma market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

### Epidemiology Insights

What is the number of prevalent cases (2018-2034) of peripheral T-cell lymphoma across the seven major markets?

What is the number of prevalent cases (2018-2034) of peripheral T-cell lymphoma by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of peripheral T-cell lymphoma by gender across the seven major markets?

What is the number of prevalent cases (2018-2034) of peripheral T-cell lymphoma by type across the seven major markets?

How many patients are diagnosed (2018-2034) with peripheral T-cell lymphoma across the seven major markets?

What is the size of the peripheral T-cell lymphoma patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of peripheral T-cell lymphoma?

What will be the growth rate of patients across the seven major markets?

### Peripheral T-cell Lymphoma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for peripheral T-cell lymphoma drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the peripheral T-cell lymphoma market?

What are the key regulatory events related to the peripheral T-cell lymphoma market?

What is the structure of clinical trial landscape by status related to the peripheral T-cell lymphoma market?

What is the structure of clinical trial landscape by phase related to the peripheral T-cell lymphoma market?

What is the structure of clinical trial landscape by route of administration related to the peripheral T-cell lymphoma market?

## Contents

### **1 PREFACE**

### **2 SCOPE AND METHODOLOGY**

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
  - 2.3.1 Primary Sources
  - 2.3.2 Secondary Sources
- 2.4 Market Estimation
  - 2.4.1 Bottom-Up Approach
  - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

### **3 EXECUTIVE SUMMARY**

### **4 PERIPHERAL T-CELL LYMPHOMA - INTRODUCTION**

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

### **5 PERIPHERAL T-CELL LYMPHOMA - DISEASE OVERVIEW**

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

### **6 PATIENT JOURNEY**

### **7 PERIPHERAL T-CELL LYMPHOMA - EPIDEMIOLOGY AND PATIENT POPULATION**

- 7.1 Epidemiology - Key Insights
- 7.2 Epidemiology Scenario - Top 7 Markets
  - 7.2.1 Epidemiology Scenario (2018-2023)
  - 7.2.2 Epidemiology Forecast (2024-2034)
  - 7.2.3 Epidemiology by Age (2018-2034)
  - 7.2.4 Epidemiology by Gender (2018-2034)
  - 7.2.5 Epidemiology by Type (2018-2034)
  - 7.2.6 Diagnosed Cases (2018-2034)
  - 7.2.7 Patient Pool/Treated Cases (2018-2034)
- 7.3 Epidemiology Scenario - United States
  - 7.3.1 Epidemiology Scenario (2018-2023)
  - 7.3.2 Epidemiology Forecast (2024-2034)
  - 7.3.3 Epidemiology by Age (2018-2034)
  - 7.3.4 Epidemiology by Gender (2018-2034)
  - 7.3.5 Epidemiology by Type (2018-2034)
  - 7.3.6 Diagnosed Cases (2018-2034)
  - 7.3.7 Patient Pool/Treated Cases (2018-2034)
- 7.4 Epidemiology Scenario - Germany
  - 7.4.1 Epidemiology Scenario (2018-2023)
  - 7.4.2 Epidemiology Forecast (2024-2034)
  - 7.4.3 Epidemiology by Age (2018-2034)
  - 7.4.4 Epidemiology by Gender (2018-2034)
  - 7.4.5 Epidemiology by Type (2018-2034)
  - 7.4.6 Diagnosed Cases (2018-2034)
  - 7.4.7 Patient Pool/Treated Cases (2018-2034)
- 7.5 Epidemiology Scenario - France
  - 7.5.1 Epidemiology Scenario (2018-2023)
  - 7.5.2 Epidemiology Forecast (2024-2034)
  - 7.5.3 Epidemiology by Age (2018-2034)
  - 7.5.4 Epidemiology by Gender (2018-2034)
  - 7.5.5 Epidemiology by Type (2018-2034)
  - 7.5.6 Diagnosed Cases (2018-2034)
  - 7.5.7 Patient Pool/Treated Cases (2018-2034)
- 7.6 Epidemiology Scenario - United Kingdom
  - 7.6.1 Epidemiology Scenario (2018-2023)
  - 7.6.2 Epidemiology Forecast (2024-2034)
  - 7.6.3 Epidemiology by Age (2018-2034)
  - 7.6.4 Epidemiology by Gender (2018-2034)
  - 7.6.5 Epidemiology by Type (2018-2034)



7.6.6 Diagnosed Cases (2018-2034)

7.6.7 Patient Pool/Treated Cases (2018-2034)

#### 7.7 Epidemiology Scenario - Italy

7.7.1 Epidemiology Scenario (2018-2023)

7.7.2 Epidemiology Forecast (2024-2034)

7.7.3 Epidemiology by Age (2018-2034)

7.7.4 Epidemiology by Gender (2018-2034)

7.7.5 Epidemiology by Type (2018-2034)

7.7.6 Diagnosed Cases (2018-2034)

7.7.7 Patient Pool/Treated Cases (2018-2034)

#### 7.8 Epidemiology Scenario - Spain

7.8.1 Epidemiology Scenario (2018-2023)

7.8.2 Epidemiology Forecast (2024-2034)

7.8.3 Epidemiology by Age (2018-2034)

7.8.4 Epidemiology by Gender (2018-2034)

7.8.5 Epidemiology by Type (2018-2034)

7.8.6 Diagnosed Cases (2018-2034)

7.8.7 Patient Pool/Treated Cases (2018-2034)

#### 7.9 Epidemiology Scenario - Japan

7.9.1 Epidemiology Scenario (2018-2023)

7.9.2 Epidemiology Forecast (2024-2034)

7.9.3 Epidemiology by Age (2018-2034)

7.9.4 Epidemiology by Gender (2018-2034)

7.9.5 Epidemiology by Type (2018-2034)

7.9.6 Diagnosed Cases (2018-2034)

7.9.7 Patient Pool/Treated Cases (2018-2034)

## **8 PERIPHERAL T-CELL LYMPHOMA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES**

8.1 Guidelines, Management and Treatment

8.2 Treatment Algorithm

## **9 PERIPHERAL T-CELL LYMPHOMA - UNMET NEEDS**

## **10 PERIPHERAL T-CELL LYMPHOMA - KEY ENDPOINTS OF TREATMENT**

## **11 PERIPHERAL T-CELL LYMPHOMA - MARKETING PRODUCTS**



## 11.1 List of Peripheral T-cell Lymphoma Marketed Drugs Across the Top 7 Markets

### 11.1.1 Beleodaq (Belinostat) - Onxeo

#### 11.1.1.1 Drug Overview

#### 11.1.1.2 Mechanism of Action

#### 11.1.1.3 Regulatory Status

#### 11.1.1.4 Clinical Trial Results

#### 11.1.1.5 Sales Across Major Markets

### 11.1.2 Adcetris (Brentuximab vedotin) - Seagen/Takeda Oncology

#### 11.1.2.1 Drug Overview

#### 11.1.2.2 Mechanism of Action

#### 11.1.2.3 Regulatory Status

#### 11.1.2.4 Clinical Trial Results

#### 11.1.2.5 Sales Across Major Markets

### 11.1.3 Folutyn (Pralatrexate) - Acrotech Biopharma

#### 11.1.3.1 Drug Overview

#### 11.1.3.2 Mechanism of Action

#### 11.1.3.3 Regulatory Status

#### 11.1.3.4 Clinical Trial Results

#### 11.1.3.5 Sales Across Major Markets

### 11.1.4 Istodax (Romidepsin) - Celgene Corporation

#### 11.1.4.1 Drug Overview

#### 11.1.4.2 Mechanism of Action

#### 11.1.4.3 Regulatory Status

#### 11.1.4.4 Clinical Trial Results

#### 11.1.4.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

## 12 PERIPHERAL T-CELL LYMPHOMA - PIPELINE DRUGS

### 12.1 List of Peripheral T-cell Lymphoma Pipeline Drugs Across the Top 7 Markets

#### 12.1.1 Tolinapant - Astex Pharmaceuticals

##### 12.1.1.1 Drug Overview

##### 12.1.1.2 Mechanism of Action

##### 12.1.1.3 Clinical Trial Results

##### 12.1.1.4 Safety and Efficacy

##### 12.1.1.5 Regulatory Status

#### 12.1.2 Duvelisib - Secura Bio

##### 12.1.2.1 Drug Overview

- 12.1.2.2 Mechanism of Action
- 12.1.2.3 Clinical Trial Results
- 12.1.2.4 Safety and Efficacy
- 12.1.2.5 Regulatory Status
- 12.1.3 AFM 13 - Affimed Therapeutics
  - 12.1.3.1 Drug Overview
  - 12.1.3.2 Mechanism of Action
  - 12.1.3.3 Clinical Trial Results
  - 12.1.3.4 Safety and Efficacy
  - 12.1.3.5 Regulatory Status
- 12.1.4 AZD 4205 - Dizal Pharmaceutical
  - 12.1.4.1 Drug Overview
  - 12.1.4.2 Mechanism of Action
  - 12.1.4.3 Clinical Trial Results
  - 12.1.4.4 Safety and Efficacy
  - 12.1.4.5 Regulatory Status
- 12.1.5 Valemetostat - Daiichi Sankyo
  - 12.1.5.1 Drug Overview
  - 12.1.5.2 Mechanism of Action
  - 12.1.5.3 Clinical Trial Results
  - 12.1.5.4 Safety and Efficacy
  - 12.1.5.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

### **13. PERIPHERAL T-CELL LYMPHOMA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS**

### **14. PERIPHERAL T-CELL LYMPHOMA – CLINICAL TRIAL LANDSCAPE**

- 14.1 Drugs by Status
- 14.2 Drugs by Phase
- 14.3 Drugs by Route of Administration
- 14.4 Key Regulatory Events

### **15 PERIPHERAL T-CELL LYMPHOMA - MARKET SCENARIO**

- 15.1 Market Scenario - Key Insights
- 15.2 Market Scenario - Top 7 Markets

- 15.2.1 Peripheral T-cell Lymphoma - Market Size
  - 15.2.1.1 Market Size (2018-2023)
  - 15.2.1.2 Market Forecast (2024-2034)
- 15.2.2 Peripheral T-cell Lymphoma - Market Size by Therapies
  - 15.2.2.1 Market Size by Therapies (2018-2023)
  - 15.2.2.2 Market Forecast by Therapies (2024-2034)
- 15.3 Market Scenario - United States
  - 15.3.1 Peripheral T-cell Lymphoma - Market Size
    - 15.3.1.1 Market Size (2018-2023)
    - 15.3.1.2 Market Forecast (2024-2034)
  - 15.3.2 Peripheral T-cell Lymphoma - Market Size by Therapies
    - 15.3.2.1 Market Size by Therapies (2018-2023)
    - 15.3.2.2 Market Forecast by Therapies (2024-2034)
  - 15.3.3 Peripheral T-cell Lymphoma - Access and Reimbursement Overview
- 15.4 Market Scenario - Germany
  - 15.4.1 Peripheral T-cell Lymphoma - Market Size
    - 15.4.1.1 Market Size (2018-2023)
    - 15.4.1.2 Market Forecast (2024-2034)
  - 15.4.2 Peripheral T-cell Lymphoma - Market Size by Therapies
    - 15.4.2.1 Market Size by Therapies (2018-2023)
    - 15.4.2.2 Market Forecast by Therapies (2024-2034)
  - 15.4.3 Peripheral T-cell Lymphoma - Access and Reimbursement Overview
- 15.5 Market Scenario - France
  - 15.5.1 Peripheral T-cell Lymphoma - Market Size
    - 15.5.1.1 Market Size (2018-2023)
    - 15.5.1.2 Market Forecast (2024-2034)
  - 15.5.2 Peripheral T-cell Lymphoma - Market Size by Therapies
    - 15.5.2.1 Market Size by Therapies (2018-2023)
    - 15.5.2.2 Market Forecast by Therapies (2024-2034)
  - 15.5.3 Peripheral T-cell Lymphoma - Access and Reimbursement Overview
- 15.6 Market Scenario - United Kingdom
  - 15.6.1 Peripheral T-cell Lymphoma - Market Size
    - 15.6.1.1 Market Size (2018-2023)
    - 15.6.1.2 Market Forecast (2024-2034)
  - 15.6.2 Peripheral T-cell Lymphoma - Market Size by Therapies
    - 15.6.2.1 Market Size by Therapies (2018-2023)
    - 15.6.2.2 Market Forecast by Therapies (2024-2034)
  - 15.6.3 Peripheral T-cell Lymphoma - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy

- 15.7.1 Peripheral T-cell Lymphoma - Market Size
  - 15.7.1.1 Market Size (2018-2023)
  - 15.7.1.2 Market Forecast (2024-2034)
- 15.7.2 Peripheral T-cell Lymphoma - Market Size by Therapies
  - 15.7.2.1 Market Size by Therapies (2018-2023)
  - 15.7.2.2 Market Forecast by Therapies (2024-2034)
- 15.7.3 Peripheral T-cell Lymphoma - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
  - 15.8.1 Peripheral T-cell Lymphoma - Market Size
    - 15.8.1.1 Market Size (2018-2023)
    - 15.8.1.2 Market Forecast (2024-2034)
  - 15.8.2 Peripheral T-cell Lymphoma - Market Size by Therapies
    - 15.8.2.1 Market Size by Therapies (2018-2023)
    - 15.8.2.2 Market Forecast by Therapies (2024-2034)
  - 15.8.3 Peripheral T-cell Lymphoma - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
  - 15.9.1 Peripheral T-cell Lymphoma - Market Size
    - 15.9.1.1 Market Size (2018-2023)
    - 15.9.1.2 Market Forecast (2024-2034)
  - 15.9.2 Peripheral T-cell Lymphoma - Market Size by Therapies
    - 15.9.2.1 Market Size by Therapies (2018-2023)
    - 15.9.2.2 Market Forecast by Therapies (2024-2034)
  - 15.9.3 Peripheral T-cell Lymphoma - Access and Reimbursement Overview

## **16 PERIPHERAL T-CELL LYMPHOMA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS**

## **17 PERIPHERAL T-CELL LYMPHOMA MARKET - SWOT ANALYSIS**

- 17.1 Strengths
- 17.2 Weaknesses
- 17.3 Opportunities
- 17.4 Threats

## **18 PERIPHERAL T-CELL LYMPHOMA MARKET – STRATEGIC RECOMMENDATIONS**

## **19 APPENDIX**

## I would like to order

Product name: Peripheral T-cell Lymphoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/P5489E88FBEBEN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P5489E88FBEBEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

